Duplicate breath testing to confirm eradication of Helicobacter pylori: incremental benefit and cost in 419 patients

被引:10
作者
Vakil, N. [1 ]
Zullo, A. [2 ]
Ricci, C. [3 ]
Hassan, C. [2 ]
Vaira, D.
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[2] Nuovo Regina Margherita Hosp, Gastroenterol Unit, Rome, Italy
[3] Univ Brescia, Gastroenterol Unit, Brescia, Italy
关键词
D O I
10.1111/j.1365-2036.2008.03846.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Current standards for establishing a cure of H. pylori infection require two breath tests taken at least 4 weeks apart, to be negative. To determine the incremental cost and accuracy of repeating a urea breath test (UBT) in clinical practice. We identified 419 patients with documented Helicobacter pylori infection who received eradication therapy and then had two breath tests, one 4 weeks and the second at least 8 weeks after the completion of treatment. H. pylori infection was documented at baseline by a positive rapid urease test and histology. In patients with successful eradication of H. pylori infection (n = 317), the mean +/- standard deviation delta over baseline (DOB) value before treatment was 43 +/- 29 ppm. Following treatment, the mean DOB in cured was 0.56 +/- 2.1 ppm at 1 month and was similar to the value obtained at the second breath (0.68 +/- 1; P = 0.39), which was performed 60 +/- 71 days after the first UBT. In patients remaining infected (n = 102), the mean DOB at baseline was 47 +/- 20 ppm. Four weeks after treatment, the DOB was 40 +/- 32 ppm. The second UBT was performed 94 +/- 72 days after the first and the DOB was significantly greater than the first (47 +/- 28; P = 0.040). There was no discordant result between the first breath test and second breath test. At a cost of 30 euros/breath test, the incremental cost of a second breath test was 12 570 euros in this cohort with no incremental clinical benefit. A single UBT, 4 weeks after treatment is as effective as two serial breath tests in confirming H. pylori eradication. The incremental cost of the second breath test is very high with no incremental clinical benefit.
引用
收藏
页码:1304 / 1308
页数:5
相关论文
共 8 条
[1]   Long-term follow-up of 13C-urea breath test results after Helicobacter pylori eradication:: frequency and significance of borderline δ13CO2 values [J].
Gisbert, JP ;
Olivares, D ;
Jimenez, I ;
Pajares, JM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (02) :275-280
[2]   The recurrence of Helicobacter pylori infection:: Incidence and variables influencing it.: A critical review [J].
Gisbert, JP .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09) :2083-2099
[3]  
Health Canada, GUID DEV THER REG ER
[4]   Levofloxacin-based triple therapy for Helicobacter pylori re-treatment:: Role of bacterial resistance [J].
Perna, F. ;
Zullo, A. ;
Ricci, C. ;
Hassan, C. ;
Morini, S. ;
Vaira, D. .
DIGESTIVE AND LIVER DISEASE, 2007, 39 (11) :1001-1005
[5]  
*US FDA, 2008, CLIN DEV LAB ANT DRU
[6]   Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication -: A randomized trial [J].
Vaira, Dino ;
Zullo, Angelo ;
Vakil, Nimish ;
Gatta, Luigi ;
Ricci, Chiara ;
Perna, Federico ;
Hassan, Cesare ;
Bernabucci, Veronica ;
Tampieri, Andrea ;
Morini, Sergio .
ANNALS OF INTERNAL MEDICINE, 2007, 146 (08) :556-145
[7]  
*WORK PART EUR HEL, 1997, GUT, V41, pS10
[8]   Clinical and histologic predictors of Helicobacter pylori infection recurrence [J].
Zullo, A ;
Rinaldi, V ;
Hassan, C ;
Taggi, F ;
Giustini, M ;
Winn, S ;
Castagna, G ;
Attili, AF .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2000, 31 (01) :38-41